Inpatient burden of COVID-19 in Japan: A retrospective cohort study

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Journal of Infection and Chemotherapy Pub Date : 2025-04-28 DOI:10.1016/j.jiac.2025.102721

Kathleen M. Andersen , Matthew A. Brouillette , Kanae Togo , Kosuke Tanabe , Benjamin T. Carter , Matthew T. Kent , Yingjie Ding , Daniel Curcio , Verna Welch , Leah J. McGrath , Bushra Ilyas , Shuhei Ito

{"title":"Inpatient burden of COVID-19 in Japan: A retrospective cohort study","authors":"Kathleen M. Andersen , Matthew A. Brouillette , Kanae Togo , Kosuke Tanabe , Benjamin T. Carter , Matthew T. Kent , Yingjie Ding , Daniel Curcio , Verna Welch , Leah J. McGrath , Bushra Ilyas , Shuhei Ito","doi":"10.1016/j.jiac.2025.102721","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Changing disease dynamics and access to COVID-19 vaccines in Japan warrant a timely description of the burden of severe disease. Here we report inpatient healthcare resource utilization of COVID-19 in Japan and contextualize results with influenza.</div></div><div><h3>Methods</h3><div>We selected persons hospitalized for COVID-19 (ICD-10 code U07.1) from April 1, 2020–January 31, 2024 or influenza (ICD-10 code J09.X–J11.x) from November 1, 2017–October 31, 2019 from Medical Data Vision, a large hospital-based database in Japan. Outcomes of interest were length of stay, intensive care unit (ICU) admission, receipt of invasive mechanical ventilation (IMV), and inpatient mortality, assessed overall, as well as stratified by age groups and calendar time.</div></div><div><h3>Findings</h3><div>Among 5684 hospitalized COVID-19 cases, persons were older (median age 80 vs 64) and had a longer length of stay (median 21 vs 5 days) than the 18,584 influenza cases. The proportions of COVID-19 patients admitted to ICU (3% vs 1%), received IMV (6% vs 3%) and died in hospital (12% vs 3%) were higher compared to those of influenza patients. Burden was higher in adult COVID-19 patients than pediatric COVID-19 patients; however, COVID-19 burden surpassed influenza burden for both adults and pediatric patients. Inpatient burden of COVID-19 between May 2023 and January 2024 remained greater than that of influenza, with five times longer length of stay, three times the frequency of ICU care, twice the IMV support and four times the in-hospital deaths.</div></div><div><h3>Interpretation</h3><div>These findings underscore the need for continued prevention and treatment of COVID-19 to prevent severe disease.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 7","pages":"Article 102721"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1341321X25001187","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Changing disease dynamics and access to COVID-19 vaccines in Japan warrant a timely description of the burden of severe disease. Here we report inpatient healthcare resource utilization of COVID-19 in Japan and contextualize results with influenza.

Methods

We selected persons hospitalized for COVID-19 (ICD-10 code U07.1) from April 1, 2020–January 31, 2024 or influenza (ICD-10 code J09.X–J11.x) from November 1, 2017–October 31, 2019 from Medical Data Vision, a large hospital-based database in Japan. Outcomes of interest were length of stay, intensive care unit (ICU) admission, receipt of invasive mechanical ventilation (IMV), and inpatient mortality, assessed overall, as well as stratified by age groups and calendar time.

Findings

Among 5684 hospitalized COVID-19 cases, persons were older (median age 80 vs 64) and had a longer length of stay (median 21 vs 5 days) than the 18,584 influenza cases. The proportions of COVID-19 patients admitted to ICU (3% vs 1%), received IMV (6% vs 3%) and died in hospital (12% vs 3%) were higher compared to those of influenza patients. Burden was higher in adult COVID-19 patients than pediatric COVID-19 patients; however, COVID-19 burden surpassed influenza burden for both adults and pediatric patients. Inpatient burden of COVID-19 between May 2023 and January 2024 remained greater than that of influenza, with five times longer length of stay, three times the frequency of ICU care, twice the IMV support and four times the in-hospital deaths.

Interpretation

These findings underscore the need for continued prevention and treatment of COVID-19 to prevent severe disease.

查看原文本刊更多论文

日本COVID-19住院患者负担：一项回顾性队列研究

背景：日本不断变化的疾病动态和COVID-19疫苗的可及性要求及时描述严重疾病的负担。在这里，我们报告了日本COVID-19住院医疗资源的利用情况，并将结果与流感联系起来。方法：选取2020年4月1日至2024年1月31日因COVID-19 （ICD-10代码U07.1）或流感（ICD-10代码J09）住院的患者。X - J11.x)从2017年11月1日至2019年10月31日，来自日本大型医院数据库Medical Data Vision。关注的结果包括住院时间、重症监护病房（ICU）入院、接受有创机械通气（IMV）和住院死亡率，并按年龄组和日历时间分层进行总体评估。结果：在5684例住院的COVID-19病例中，患者年龄较大（中位年龄80 vs 64），住院时间较长（中位年龄21 vs 5天），而流感病例则为18584例。COVID-19患者入住ICU（3%对1%）、接受IMV（6%对3%）和院内死亡（12%对3%）的比例高于流感患者。成人COVID-19患者的负担高于儿童COVID-19患者，尽管成人和儿童患者的COVID-19负担都超过了流感。2023年5月至2024年1月期间，COVID-19的住院患者负担仍高于流感，住院时间长5倍，需要ICU护理的次数多（高3倍），IMV支持多（高2倍），院内死亡多（高4倍）。解释：这些发现强调了继续预防和治疗COVID-19以预防严重疾病的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Chemotherapy INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY

CiteScore

4.10

自引率

4.50%

发文量

303

审稿时长

47 days

期刊介绍： The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.